Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study
Breast Cancer Research and Treatment · 2026
DOI: 10.1007/s10549-026-07930-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Michelle Sterpi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA. msterpi@montefiore.org. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Immunotherapy, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Purpose
Immune-related adverse events (irAEs) have emerged as a potential surrogate marker for immunotherapy response across tumor types. We evaluated the association between irAEs and pathologic complete response (pCR) in a racially diverse cohort of patients with triple-negative breast cancer (TNBC) treated with neoadjuvant chemoimmunotherapy.
Methods
We conducted a retrospective analysis of 46 patients with early-stage TNBC treated with neoadjuvant chemoimmunotherapy between January 2021 and March 2023 at a single NCI-designated Comprehensive Cancer Center. irAEs, tumor-infiltrating lymphocytes (TILs), and clinicopathologic characteristics were abstracted from the medical record. Associations with pCR were analyzed using Fisher’s exact and Wilcoxon rank-sum tests.
Results
Among 46 patients, the median age was 60.5 years. Most identified as Black (n = 27, 58.7%) or Hispanic (n = 14, 30.4%). irAEs occurred in 13 patients (28.2%), most commonly hypothyroidism, rash, and arthritis. The pCR rate was 55.8% (24/43 evaluable patients). Patients who developed irAEs were more likely to achieve pCR (84.6% vs. 45.2%, p = 0.039). Higher TILs (median 29%) were associated with pCR both as a continuous variable (p = 0.004) and categorically (p = 0.002), but not with irAE development (p = 0.341). pCR was more common among Hispanic patients (p = 0.005), and inversely associated with Black race (p = 0.003) and older age (p = 0.028).
Conclusion
IrAEs may serve as a surrogate for treatment response to neoadjuvant chemoimmunotherapy in early TNBC. Additionally, racial and age-based differences in treatment response suggest underlying immunologic or biologic variation. These findings highlight the importance of diverse cohort representation in immunotherapy studies and warrant validation in prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA. msterpi@montefiore.org.
- Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, USA.
- Albert Einstein College of Medicine, Bronx, NY, USA.
Zitieren
APA
Sterpi, M., Dreyfus, N., Lo, Y., Fineberg, S., Gill, H., & Makower, D. (2026). Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-07930-8
Vancouver
Sterpi M, Dreyfus N, Lo Y, Fineberg S, Gill H, Makower D. Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-07930-8
BibTeX
@article{Sterpi2026,
author = {Sterpi, Michelle and Dreyfus, Nechama and Lo, Yungtai and Fineberg, Susan and Gill, Harjot and Makower, Della},
title = {Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study},
journal = {Breast Cancer Research and Treatment},
year = {2026},
doi = {10.1007/s10549-026-07930-8}
}
EUVIMED